Retinal vasculitis

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Retrieved on: 
木曜日, 5月 16, 2024
Cloud, Patient, Justice, News, Retinal scan, Paratriathlon, EPA, Safety, SAN, Public, APLS, Retinal vasculitis, OSA, Complaint, LLP, CMI, Society, Retina, ASRS, Environment, Physician, Inflammation, DOJ, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.
  • Johnson Fistel LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy

Retrieved on: 
月曜日, 5月 6, 2024
AMD, FDA, Safety, Retinal vasculitis, Conference call, Conference, Arm, Disease, TKI, Therapy, Patient, DME, Diabetic retinopathy, Endophthalmitis, Retina, Anti-VEGF, Pharmaceutical industry

WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). The data demonstrated that DURAVYU has a biologic effect in patients with NPDR with a favorable safety and tolerability profile, however the trial did not meet the pre-specified primary endpoint. The Company plans to provide an update on the path forward for DURAVYU as a potential treatment in NPDR following a review of the full 12-month data.

Key Points: 
  • “The objective of the PAVIA trial was, for the first time, to evaluate DURAVYU as a potential treatment in a non-proliferative diabetic patient population,” said Jay Duker, M.D., Chief Executive Officer of EyePoint Pharmaceuticals.
  • I would like to thank the patients, the investigators and their site staff who participated in the PAVIA trial.
  • PAVIA is a 12-month, randomized, controlled Phase 2 clinical trial of DURAVYU in patients with moderately-severe to severe NPDR.
  • A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com .

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
火曜日, 3月 19, 2024
Cloud, OSA, APLS, ASRS, Environment, Patient, Public, Inflammation, News, LLP, Retinal scan, DOJ, Complaint, CMI, Retinal vasculitis, EPA, Justice, Society, Retina, Safety, Paratriathlon, Physician, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.
  • Johnson Fistel LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
火曜日, 3月 5, 2024
Cloud, Complaint, SAN, ASRS, DRVN, APLS, OSA, Physician, Inflammation, Retina, News, Holding, Retinal scan, Safety, Society, Patient, Retinal vasculitis, LLP, Paratriathlon, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Driven Brands Holdings, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Driven Brands Holdings, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
火曜日, 1月 16, 2024
Transfer, Cloud, Patient, Bureau, LLP, Electronic Fund Transfer Act, Knowledge, Retinal vasculitis, ASRS, Retinal scan, Society, Consumer, KeyBank, Paratriathlon, Safety, Inflammation, NII, ACI, Retina, Complaint, News, Physician

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
木曜日, 12月 14, 2023
Transfer, Cloud, Retinal vasculitis, KeyBank, Physician, LLP, ASRS, Complaint, Retinal scan, Society, Consumer, News, Inflammation, ACI, Electronic Fund Transfer Act, Bureau, Knowledge, NII, Patient, Safety, Paratriathlon, Retina

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, ACI Worldwide, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
水曜日, 12月 6, 2023
Transfer, Cloud, Retinal vasculitis, KeyBank, Physician, LLP, ASRS, Complaint, Retinal scan, Society, Consumer, News, Inflammation, ACI, Electronic Fund Transfer Act, Bureau, Knowledge, NII, Patient, Safety, Paratriathlon, Retina

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Due to weaknesses in its information security practices, ACI caused the erroneous bill payment orders to be sent to consumers’ banks for processing.

APELLIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Apellis Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
金曜日, 11月 3, 2023
Wedbush Securities, Food, Retinal scan, Physician, ASRS, Inflammation, Telephone, News, Geographic atrophy, Injection, Regulation of tobacco by the U.S. Food and Drug Administration, Society, P.C, Retinal vasculitis, Vasculitis, Complaint, Risk, Clinical trial, GA, Paratriathlon, Safety, Autoimmunity, Patient, Retina, First, APLS, Cryptocurrency, Pharmaceutical industry

Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Apellis have breached their fiduciary duties to the company.
  • Apellis is a commercial-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases.
  • SYFOVRE is designed to provide comprehensive control of the complement cascade, part of the body’s immune system.
  • Apellis also stated that the company is evaluating an eighth reported event of retinal vasculitis, which Apellis had not yet confirmed.

Investigation Alert Apellis Pharmaceuticals, KeyCorp, RTX Corporation, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
月曜日, 10月 30, 2023
Cloud, RTX, GTF, Complaint, NYSE, Retinal scan, Physician, ASRS, News, NII, Inflammation, Society, KeyBank, Retinal vasculitis, LLP, Raytheon Technologies, Paratriathlon, Safety, Patient, Retina, Pharmaceutical industry, Cryptocurrency, Insurance, Tobacco

Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • If you have continuously owned Apellis Pharmaceuticals shares since before January 28, 2021, submit your information below:
    Recently a class action lawsuit was filed against the company.
  • Johnson Fistel, LLP is investigating potential claims on behalf of KeyCorp against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Innovent Presents Clinical Data of Two Ophthalmic Bispecific Antibodies IBI302 (anti-VEGF/complement) and IBI324 (anti-VEGF-A/Ang-2) at American Academy of Ophthalmology (AAO) Annual Meeting 2023

Retrieved on: 
月曜日, 11月 6, 2023
NAMD, Neovascularization, HKEX, CFP, Trial of the century, CST, Incidence, Eye, Ophthalmology, Infrared spectroscopy correlation table, Treatment, DME, AAO, Injection, Fibrosis, MAD, SAD, Inflammation, Drug development, SAE, Retinal vasculitis, Anetoderma, Diabetic retinopathy, American Academy, American Academy of Ophthalmology, Annual general meeting, Paratriathlon, Safety, Visual acuity, Moran Eye Center, Patient, Hospital, Anti-VEGF, Pharmaceutical industry, Phosphorus, Food and Drug Administration Safety and Innovation Act

The primary endpoint was the change from baseline in best-corrected visual acuity (BCVA) in the study eye at 36 weeks.

Key Points: 
  • The primary endpoint was the change from baseline in best-corrected visual acuity (BCVA) in the study eye at 36 weeks.
  • In terms of safety, the incidence of adverse events were similar in the IBI302 2 mg group, IBI302 4 mg group, and the aflibercept 2 mg group.
  • This is a Phase 1 clinical study evaluating the safety, tolerability, and efficacy of IBI324 in the treatment of DME (ClinicalTrials.gov: NCT05489718).
  • We look forward to advancing the clinical development progress and hope Innovent's innovative medicines can benefit more patients."